A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.
Latest Information Update: 25 Jun 2025
At a glance
- Drugs Tirzepatide (Primary) ; Ixekizumab
- Indications Obesity; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms TOGETHER AMPLIFY-PsA
- Sponsors Eli Lilly and Company
Most Recent Events
- 19 Jun 2025 Planned End Date changed from 1 Jan 2027 to 1 Feb 2027.
- 19 Jun 2025 Planned primary completion date changed from 1 Jan 2027 to 1 Feb 2027.
- 27 Mar 2025 Status changed from not yet recruiting to recruiting.